脊椎生技药品市场－全球产业规模、份额、趋势、机会及预测（按产品、手术、最终用户、地区和竞争格局划分，2021-2031年）

全球脊椎生技药品市场预计将从 2025 年的 38.8 亿美元成长到 2031 年的 52.1 亿美元，复合年增长率为 5.04%。

这个领域主要包括骨移植材料、骨形成蛋白和细胞基质等特殊生物材料，这些材料对于促进脊椎融合手术中的骨骼生长和癒合至关重要。推动这一增长的关键因素是全球人口老化导致退化性脊椎疾病风险增加，以及人们越来越倾向于微创手术技术，而微创手术则需要具有强骨诱导特性的药物。美国脊椎註册中心的数据证实了这个不断增长的需求。数据显示，预计到2024年，脊椎手术数量将比前一年增加17.86%，这将直接推动生物製药的消耗。

儘管市场呈现正面势头，但高端生物製药价格高昂以及医保机构严格的报销通讯协定仍构成重大障碍。外科医生和医院在干细胞疗法和生长因子等先进疗法方面，往往面临医疗覆盖范围不稳定的问题，并承受着选择更经济实惠的替代方案的经济压力。因此，这些经济限制阻碍了新型、更昂贵的脊椎生物製药的商业性化应用，有效减缓了高级产品在医疗保健领域的渗透速度。

市场驱动因素

全球人口老化加剧，脊髓退化疾病的盛行率不断上升，这是推动市场成长的主要因素。人口结构变化导致需要进行脊椎融合手术的病例数量增加，从而对能够确保骨癒合困难患者成功实现骨融合的有效骨诱导剂产生了持续增长的需求。这一趋势也体现在该行业强劲的财务业绩中。例如，Orthofix Medical Inc. 在 2024 年 11 月公布财报中显示，其骨生长治疗部门的净销售额增加了 9%。同样，Stryker 公司截至 2024 年 10 月的财年业绩显示，其整形外科和脊椎部门的净销售额增长了 10.7%，这证实了手术量的健康復苏正在支撑整个行业的需求。

同时，合成骨移植材料的技术创新正在透过减少自体骨移植的需求来重新定义临床实践。外科医生越来越多地选择新一代骨移植材料，这些材料具有更优异的操作性和可预测的骨癒合效果，并避免了与传统取骨手术相关的併发症风险。这种向先进基质的转变正在推动旨在复製天然骨结构的产品迅速普及。例如，Kuros Biosciences公司在2024年8月报告称，其专有骨移植材料MagnetOs的直接销售额在上半年飙升了159%，这标誌着市场正发生重大转变，转向能够提高手术效率的先进合成解决方案。

市场挑战

由于高品质生物製品的高昂采购成本以及严格的报销政策，该领域面临许多挑战。许多医疗机构营运资金捉襟见肘，难以证明购买昂贵的骨形成蛋白（BMP）和细胞基质的合理性，尤其是在有更经济实惠的替代品（例如合成材料）可供选择的情况下。因此，医院采购部门为了确保财务永续性，往往会限制外科医生使用这些高端产品，从而限制了此类先进产品类型的收入成长潜力。

主要支付方的支付率下降和政策变化加剧了这些财务挑战。据北美脊椎协会 (NASS) 称，美国医疗保险和医疗补助服务中心 (Medicare & Medicaid Services) 将 2024 年的医生收费标准转换係数降低了约 3.4%，这进一步加剧了复杂脊椎手术的经济压力。由于医疗服务提供者寻求降低每次手术的营运成本，这些报销减少抑制了昂贵生物製药的使用，从而阻碍了高端解决方案的普及，并推动市场转向利润率低的同质化产品。

市场趋势

胜肽增强型骨诱导材料的出现正在改变市场格局。这类材料引入了模拟胶原蛋白细胞结合域的合成生物活性物质，从而促进骨骼修復。与存在安全隐患且高成本的传统生长因子不同，这些基于胜肽的创新技术能够直接刺激成骨细胞，为脊椎融合手术提供了一种标靶治疗方法。其临床疗效正推动着监管部门的核准和商业性的成功。例如，2025年6月，Cerapedics公司宣布，其专有的PearlMatrix植入物的一项关键性研究表明，与自体移植相比，使用该植入物的患者在六个月时达到融合的比例是其两倍以上，凸显了这类新型生物製药製剂的巨大潜力。

同时，新一代脱矿骨基质载体的进步正在满足复杂手术中对改善移植骨固定和操作的迫切需求。製造商正从标准的糊状和颗粒状配方过渡到具有更优异吸收性和互连孔隙率的先进纤维基载体，从而确保微创手术中移植骨的稳定性。这项创新正在推动主要企业的显着收入成长。 Bioventus公司报告称，其外科解决方案部门2025年11月的净销售额达到5,020万美元（年增9.3%），这一显着增长主要归功于先进骨移植替代物的广泛应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球脊椎生技药品市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（脊椎同种异体移植、骨移植替代物、细胞基质）
  • 透过手术（颈椎前路椎间盘切除融合术（ACDF）、椎间椎间融合（TLIF）、腰椎后路椎间融合（PLIF）、腰椎前路椎间融合（ALIF）、腰椎侧方椎间融合（LLIF））
  • 依最终用户（医院、门诊机构）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美脊椎生技药品市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲脊椎生技药品市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区脊椎生技药品市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲脊椎生技药品市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲脊椎生技药品市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球脊椎生技药品市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Medtronic
• Stryker
• NuVasive
• Zimmer Biomet
• SeaSpine
• DePuy Synthes
• Orthofix
• Globus Medical
• RTI Surgical
• Baxter

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Spine Biologics Market is projected to expand from USD 3.88 Billion in 2025 to USD 5.21 Billion by 2031, reflecting a compound annual growth rate of 5.04%. This sector comprises a specialized range of biomaterials, such as bone grafts, bone morphogenetic proteins, and cell-based matrices, which are essential for promoting bone growth and healing during spinal fusion surgeries. The primary forces propelling this growth are the aging global population, which is increasingly prone to degenerative spinal conditions, and the growing preference for minimally invasive surgical techniques that require potent osteoinductive agents. Evidence of this expanding demand is highlighted by data from the American Spine Registry, which reported a 17.86% increase in spinal procedure volumes in 2024 compared to the previous year, directly driving consumption of these biological products.

Despite this positive momentum, the market encounters significant hurdles related to the high price of premium biological solutions and rigorous reimbursement protocols imposed by healthcare payers. Surgeons and hospitals often face inconsistent insurance coverage for advanced treatments like stem cell therapies and growth factors, creating financial pressure to select more affordable alternatives. Consequently, these economic constraints limit the widespread commercial adoption of newer, high-end spinal biologics, effectively slowing the penetration of premium products within the broader medical landscape.

Market Driver

The escalating prevalence of degenerative spinal disorders among an aging global population serves as a major engine for market growth. As demographic shifts lead to a higher incidence of conditions requiring spinal fusion, there is a sustained and increasing need for effective osteoinductive agents to ensure successful bone healing in compromised patients. This trend is evidenced by robust financial performance in the sector; for instance, Orthofix Medical Inc. reported a 9% increase in net sales for their Bone Growth Therapies segment in their November 2024 earnings release. Similarly, Stryker's October 2024 operating results showed a 10.7% rise in Orthopaedics and Spine net sales, underscoring a healthy recovery in procedural volumes that supports widespread industry demand.

Concurrently, technological innovation in synthetic scaffolds is redefining clinical practices by lessening the need for autografts. Surgeons are increasingly turning to next-generation bone grafts that provide superior handling characteristics and predictable fusion results without the morbidity risks associated with traditional bone harvesting. This transition toward advanced matrices is fueling rapid adoption of products designed to replicate natural bone structure. A prime example is Kuros Biosciences, which reported in August 2024 that direct sales of its MagnetOs bone graft surged by 159% in the first half of the year, demonstrating a significant market shift toward scientifically advanced synthetic solutions that improve surgical efficiency.

Market Challenge

The sector faces substantial obstacles due to the high acquisition costs of premium biological products coupled with stringent reimbursement policies. Healthcare institutions, often operating under tight financial constraints, frequently find it difficult to justify the expenditure required for expensive bone morphogenetic proteins or cell-based matrices when more affordable alternatives, such as synthetics, are available. As a result, hospital procurement teams often limit surgeon access to these high-end items to ensure financial sustainability, which in turn restricts the revenue growth potential for advanced product categories.

These financial challenges are intensified by reductions in payment rates and policy changes from major payers. According to the North American Spine Society, the Centers for Medicare & Medicaid Services enacted a nearly 3.4 percent reduction in the physician fee schedule conversion factor in 2024, creating a tougher economic landscape for complex spinal surgeries. Such cuts in reimbursement discourage the use of expensive biologics as providers attempt to lower overhead costs per procedure, ultimately dampening the adoption of premium solutions and steering the market toward commoditized, lower-margin options.

Market Trends

The market is being transformed by the emergence of peptide-enhanced osteoinductive materials, which introduce synthetic bioactive agents designed to mimic the cell-binding domains of collagen for accelerated bone repair. In contrast to traditional growth factors that may present safety concerns or high costs, these peptide-based innovations directly stimulate osteoblasts, providing a targeted approach for spinal fusion. This clinical efficacy is driving regulatory success and commercial validation; for example, Cerapedics Inc. announced in June 2025 that the pivotal study for its PearlMatrix graft showed it achieved fusion in over twice as many patients at six months compared to local autograft, highlighting the potent potential of this new biologics class.

Simultaneously, the evolution of next-generation demineralized bone matrix carriers is meeting the urgent need for better graft containment and handling during complex surgeries. Manufacturers are moving away from standard putty or particulate formulations toward advanced fiber-based carriers that offer superior wicking properties and interconnected porosity, ensuring graft stability during minimally invasive procedures. This innovation is generating significant revenue growth for key players; Bioventus Inc. reported in November 2025 that its Surgical Solutions segment achieved $50.2 million in net sales, a 9.3% increase attributed largely to the strong adoption of these advanced bone graft substitutes.

Key Market Players

• Medtronic
• Stryker
• NuVasive
• Zimmer Biomet
• SeaSpine
• DePuy Synthes
• Orthofix
• Globus Medical
• RTI Surgical
• Baxter

Report Scope

In this report, the Global Spine Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Spine Biologics Market, By Product

• Spinal Allografts
• Bone Graft Substitutes
• Cell-based Matrix

Spine Biologics Market, By Surgery

• Anterior Cervical Discectomy and Fusion (ACDF)
• Transforaminal Lumbar Interbody Fusion (TLIF)
• Posterior Lumbar Interbody Fusion (PLIF)
• Anterior Lumbar Interbody Fusion (ALIF)
• Lateral Lumbar Interbody Fusion (LLIF)

Spine Biologics Market, By End User

• Hospitals
• Outpatient Facilities

Spine Biologics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Spine Biologics Market.

Available Customizations:

Global Spine Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Spine Biologics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Spinal Allografts, Bone Graft Substitutes, Cell-based Matrix)
  • 5.2.2. By Surgery (Anterior Cervical Discectomy and Fusion (ACDF), Transforaminal Lumbar Interbody Fusion (TLIF), Posterior Lumbar Interbody Fusion (PLIF), Anterior Lumbar Interbody Fusion (ALIF), Lateral Lumbar Interbody Fusion (LLIF))
  • 5.2.3. By End User (Hospitals, Outpatient Facilities)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Spine Biologics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Surgery
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Spine Biologics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Surgery
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Spine Biologics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Surgery
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Spine Biologics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Surgery
      • 6.3.3.2.3. By End User

7. Europe Spine Biologics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Surgery
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Spine Biologics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Surgery
      • 7.3.1.2.3. By End User
  • 7.3.2. France Spine Biologics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Surgery
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Spine Biologics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Surgery
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Spine Biologics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Surgery
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Spine Biologics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Surgery
      • 7.3.5.2.3. By End User

8. Asia Pacific Spine Biologics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Surgery
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Spine Biologics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Surgery
      • 8.3.1.2.3. By End User
  • 8.3.2. India Spine Biologics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Surgery
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Spine Biologics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Surgery
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Spine Biologics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Surgery
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Spine Biologics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Surgery
      • 8.3.5.2.3. By End User

9. Middle East & Africa Spine Biologics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Surgery
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Spine Biologics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Surgery
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Spine Biologics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Surgery
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Spine Biologics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Surgery
      • 9.3.3.2.3. By End User

10. South America Spine Biologics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Surgery
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Spine Biologics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Surgery
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Spine Biologics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Surgery
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Spine Biologics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Surgery
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Spine Biologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Medtronic
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Stryker
• 15.3. NuVasive
• 15.4. Zimmer Biomet
• 15.5. SeaSpine
• 15.6. DePuy Synthes
• 15.7. Orthofix
• 15.8. Globus Medical
• 15.9. RTI Surgical
• 15.10. Baxter

16. Strategic Recommendations

17. About Us & Disclaimer